Evaluation of Efficacy and Safety of E004 in Children With Asthma

Inclusion Criteria:

- Generally healthy male, and premenarchal female, children aged 4 - 11 years upon
Screening.

- With documented asthma, requiring inhaled epinephrine or beta2-agonist treatment, with
or without concurrent anti-inflammatory therapies for at least 6-months prior to
Screening.

- Being capable of performing spirometry for FEV1

- Satisfying criteria of asthma

- Can tolerate withholding treatment with inhaled bronchodilators and other allowed
medications for the minimum washout periods

- Demonstrating a Screening Baseline FEV1 that is 50 - 90% of Polgar predicted normal
value.

- Demonstrating an Airway Reversibility,

- Demonstrating satisfactory techniques in the use of a metered-dose inhaler (MDIs) and
a hand held peak expiratory flow meter, after training.

- Has been properly consented to participate in this study.

Exclusion Criteria:

- Any current or past medical conditions that, per investigator discretion, might
significantly affect pharmacodynamic responses to the study drugs

- Concurrent clinically significant cardiovascular, hematological, renal, neurologic,
hepatic, endocrine, psychiatric, or malignant diseases.

- Known intolerance or hypersensitivity to any component of the study drugs

- Recent infection of the respiratory tract

- Use of prohibited medications

- Having been on other investigational drug/device studies in the last 30 days prior to
screening.